Lytgobi (futibatinib)
ConditionalAdditional monitoring
- Region
- 🇪🇺 EU
- Active substance
- futibatinib
- Company
- Taiho Pharma Netherlands B.V.
- Status
- Authorised
- Therapeutic area
- Cholangiocarcinoma
- CHMP opinion
- Wed 26 Apr 2023
- EU approval
- Tue 04 Jul 2023
- Designations
- Conditional, Additional monitoring
- Application
- EMEA/H/C/005627
- ATC
- L01EN04
- Official record
- www.ema.europa.eu
Indication
Lytgobi monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.
Regulatory milestones
No milestones recorded in the last year.
Follow Lytgobi
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.